skip to main content
Idioma:
Refinado por: Nome da Publicação: European Journal Of Cancer Supplements remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
Material Type:
Artigo 		Adicionar ao Meu Espaço

1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

Xu, C ; Reck, B ; Xue, Z ; Huang, L ; Baker, K ; Chen, M ; Mooser, V ; Cardon, L ; Spraggs, C ; Pandite, L

European journal of cancer supplements, 2009, Vol.7 (2), p.119-119 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC
9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC

Reck, M ; Ramlau, R ; VonPawel, J ; Antonio, B. San ; Visseren-Grul, C ; Chouaki, N ; Eschbach, C ; Szczesna, A ; Vansteenkiste, J

European journal of cancer supplements, 2009, Vol.7 (2), p.528-528 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
3
9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC
9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

Zielinski, M ; Laskowski, U ; Bieselt, R ; Reck, M ; Strausz, J ; Perdeus, J ; Park, K ; Atanackovic, D ; Debois, M ; Debruyne, C

European journal of cancer supplements, 2009, Vol.7 (2), p.511-512 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
4
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)

Leighl, N ; Reck, M ; de Haas, S ; Evers, S ; Delmar, P ; Manegold, C ; Scherer, S

European journal of cancer supplements, 2009, Vol.7 (2), p.558-558 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer
9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer

Stopfer, P ; Freiwald, M ; Liesenfeld, K.H ; Bruno, R ; Hodge, L ; Eschbach, C ; Reck, M ; von Pawel, J ; Kaiser, R ; Staab, A

European journal of cancer supplements, 2009, Vol.7 (2), p.551-551 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
6
6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer
6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer

Gatzemeier, U ; vonPawel, J ; Eschbach, C ; Brune, A ; Wagner, A ; Giurescu, M ; Reck, M

European journal of cancer supplements, 2007, Vol.5 (4), p.378-378 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
6512 ORAL Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT study
6512 ORAL Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT study
Material Type:
Artigo 		Adicionar ao Meu Espaço

6512 ORAL Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT study

Reck, M ; Milanowski, J ; Au, S.K ; Yang, P.C ; Akimov, M ; Duymelinck, C ; Gutjahr, T ; McLoughlin, P ; Hillenbach, C ; Felip, E

European journal of cancer supplements, 2007, Vol.5 (4), p.360-360 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704
6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704
Material Type:
Artigo 		Adicionar ao Meu Espaço

6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704

Eberhardt, W ; Reck, M ; vonPawel, J ; Zatloukal, P ; Ramlau, R ; Gorbounova, V ; Leighl, N ; Mezger, J ; Moore, N ; Manegold, C

European journal of cancer supplements, 2007, Vol.5 (4), p.362-362 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study
6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study

Ranson, M ; Reck, M ; Anthoney, A ; Hanauske, A ; Akimov, M ; Klingelschmitt, G ; Kletzl, H ; Twelves, C

European journal of cancer supplements, 2007, Vol.5 (4), p.384-384 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study
6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study
Material Type:
Artigo 		Adicionar ao Meu Espaço

6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study

Smit, E ; Reck, M ; Krzakowski, M ; Gridelli, C ; Curescu, S ; Berzinec, P ; Barata, F ; McDermott, R ; Jovanovic, D ; Magyar, P

European journal of cancer supplements, 2007, Vol.5 (4), p.359-359 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.